Literature DB >> 12583903

A novel aldo-keto reductase from Escherichia coli can increase resistance to methylglyoxal toxicity.

Anne W Grant1, Gavin Steel, Hugh Waugh, Elizabeth M Ellis.   

Abstract

A novel aldo-keto reductase (AKR) from Escherichia coli has been cloned, expressed and purified. This protein, YghZ, is distantly related (<40%) to mammalian aflatoxin dialdehyde reductases of the aldo-keto reductase AKR7 family and to potassium channel beta-subunits in the AKR6 family. The enzyme has been placed in a new AKR family (AKR14), with the designation AKR14A1. Sequences encoding putative homologues of this enzyme exist in many other bacteria. The enzyme can reduce several aldehyde and diketone substrates, including the toxic metabolite methylglyoxal. The K(m) for the model substrate 4-nitrobenzaldehyde is 1.06 mM and for the endogenous dicarbonyl methylglyoxal it is 3.4 mM. Overexpression of the recombinant enzyme in E. coli leads to increased resistance to methylglyoxal. It is possible that this enzyme plays a role in the metabolism of methylglyoxal, and can influence its levels in vivo.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12583903     DOI: 10.1111/j.1574-6968.2003.tb11503.x

Source DB:  PubMed          Journal:  FEMS Microbiol Lett        ISSN: 0378-1097            Impact factor:   2.742


  18 in total

1.  Selective enzymatic reduction of aldehydes.

Authors:  Guido Sello; Fulvia Orsini; Silvana Bernasconi; Patrizia Di Gennaro
Journal:  Molecules       Date:  2006-05-12       Impact factor: 4.411

2.  Identification and functional characterization of four novel aldo/keto reductases in Anabaena sp. PCC 7120 by integrating wet lab with in silico approaches.

Authors:  Chhavi Agrawal; Shivam Yadav; Shweta Rai; Antra Chatterjee; Sonia Sen; Ruchi Rai; L C Rai
Journal:  Funct Integr Genomics       Date:  2017-02-11       Impact factor: 3.410

3.  The unusual antibacterial activity of medical-grade Leptospermum honey: antibacterial spectrum, resistance and transcriptome analysis.

Authors:  S E Blair; N N Cokcetin; E J Harry; D A Carter
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-06-10       Impact factor: 3.267

4.  A structural characterization of the isoniazid Mycobacterium tuberculosis drug target, Rv2971, in its unliganded form.

Authors:  Adam Shahine; Anggia Prasetyoputri; Jamie Rossjohn; Travis Beddoe
Journal:  Acta Crystallogr F Struct Biol Commun       Date:  2014-04-17       Impact factor: 1.056

5.  Evolution-guided optimization of biosynthetic pathways.

Authors:  Srivatsan Raman; Jameson K Rogers; Noah D Taylor; George M Church
Journal:  Proc Natl Acad Sci U S A       Date:  2014-12-01       Impact factor: 11.205

6.  Overproduction of a rice aldo-keto reductase increases oxidative and heat stress tolerance by malondialdehyde and methylglyoxal detoxification.

Authors:  Zoltán Turóczy; Petra Kis; Katalin Török; Mátyás Cserháti; Agnes Lendvai; Dénes Dudits; Gábor V Horváth
Journal:  Plant Mol Biol       Date:  2011-01-19       Impact factor: 4.076

7.  Conversion of methylglyoxal to acetol by Escherichia coli aldo-keto reductases.

Authors:  Junsang Ko; Insook Kim; Seokho Yoo; Bumchan Min; Kyungmin Kim; Chankyu Park
Journal:  J Bacteriol       Date:  2005-08       Impact factor: 3.490

8.  Metabolite profiling reveals YihU as a novel hydroxybutyrate dehydrogenase for alternative succinic semialdehyde metabolism in Escherichia coli.

Authors:  Natsumi Saito; Martin Robert; Hayataro Kochi; Goh Matsuo; Yuji Kakazu; Tomoyoshi Soga; Masaru Tomita
Journal:  J Biol Chem       Date:  2009-04-16       Impact factor: 5.157

9.  Toward aldehyde and alkane production by removing aldehyde reductase activity in Escherichia coli.

Authors:  Gabriel M Rodriguez; Shota Atsumi
Journal:  Metab Eng       Date:  2014-08-07       Impact factor: 9.783

10.  Macro-to-micro structural proteomics: native source proteins for high-throughput crystallization.

Authors:  Monica Totir; Nathaniel Echols; Max Nanao; Christine L Gee; Alisa Moskaleva; Scott Gradia; Anthony T Iavarone; James M Berger; Andrew P May; Chloe Zubieta; Tom Alber
Journal:  PLoS One       Date:  2012-02-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.